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Abstract: A new series of nortopsentin analogues, in which the imidazole ring of the 
natural product was replaced by thiazole and the indole unit bound to position 2 of the 
thiazole ring was substituted by a 7-azaindole moiety, was efficiently synthesized. Two of 
the new nortopsentin analogues showed good antiproliferative effect against the totality of 
the NCI full panel of human tumor cell lines (~60) having GI50 values ranging from low 
micromolar to nanomolar level. The mechanism of the antiproliferative effect of these 
derivatives, investigated on human hepatoma HepG2 cells, was pro-apoptotic, being associated 
with externalization of plasma membrane phosphatidylserine and mitochondrial dysfunction. 
Moreover, the compounds induced a concentration-dependent accumulation of cells in the 
subG0/G1phase, while confined viable cells in G2/M phase. 
Keywords: marine alkaloids; indolyl alkaloids; nortopsentin analogues; 3-[4-(1H-indol-3-
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1. Introduction 
New natural or synthetic heterocyclic scaffolds have been recently identified and developed as possible 
anticancer agents [1–19]. Among the various natural sources, viz plants, microbes, animals, and marine 
organisms, the latter are increasingly contributing a large number of biologically active alkaloids. An 
important class of deep-sea sponge metabolites with remarkable biological activities, such as  
anti-inflammatory, antimicrobial, antiviral, and antitumor, is constituted by bis-indolyl alkaloids, 
characterized by two indole units connected, through their position 3, by a spacer [20–23]. 
The bis-indolyl alkaloid spacer can have several structural features such as an acyclic chain or a 
carbocyclic ring. Thus, hyrtiosin B, isolated from Hyrtios erecta, 2,2-bis(6′-bromo-3′-indolyl)ethylamine, 
isolated from the tunicate Didemnum candidum and Coscinamides A–C, isolated from deep marine sponge 
Coscinoderma, showed antiproliferative or anti-HIV activity, as well as asterriquinone, isolated from 
Aspergillus fungi, and bearing a six-membered carbocyclic symmetrical structure (Chart 1) [24–27].  
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Chart 1. bis-Indolyl alkaloids with acyclic and carbocyclic spacers. 
The spacer can also be constituted by differently sized heterocycles. Thus, dragmacidin and 
dragmacidins A−E, isolated from a large number of deep water sponges such as Dragmacidon,  
Halicortex, Spongosorites, Hexadella and the tunicate Didemnum candidum, exhibit the saturated  
six-membered heterocyclic link piperazine or a pyrazinone spacer, and showed several biological properties 
(Chart 2) [25,28–31].  
More recently, hyrtinadine A, isolated from the marine sponge Hyrtios and bearing a pyrimidine ring as 
a spacer, exhibited in vitro cytotoxicity [32]. 
Topsentins A, B1 and B2, which were isolated from Mediterranean sponge Topsentia genitrix, bear a  
2-acyl imidazole spacer and showed antitumor and antiviral activities [33]. Later, from Spongosorites sp. 
and from Hexadella sp. were obtained the same natural products, which were named deoxy-topsentin, 
topsentin, and bromotopsentin, respectively [34,35]. More recently, topsentin C, isobromotopsentin, 
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bromodeoxytopsentin, and its isomer isobromodeoxytopsentin, were isolated from Hexadella sp., 
Spongosorites sp and Spongosorites genitrix, respectively [29,36–38]. 
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Chart 2. bis-Indolyl alkaloids and analogues with heterocyclic spacers. 
Nortopsentins A−C, isolated from Spongosorites ruetzleri, have a 2,4-disubstituted imidazole ring as a 
spacer and showed in vitro cytotoxicity against P388 cells (IC50, 4.5–20.7 μM). Methylation  
of the two-indole nitrogen atoms produced a significant improvement in cytotoxicity (IC50,  
0.64–1.70 μM) [39]. 
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Since marine organisms allow the isolation of very small amount of the biologically active substances 
from the natural material, several total synthesis of nortopsentins were proposed [40–43]. Moreover, due to 
the considerable activities shown, indolyl alkaloids have attracted remarkable attention by researchers 
becoming an interesting field in medicinal chemistry. Thus, several dragmacidin analogues bearing six 
membered heterocycles, such as pyridine, pyrazine, pyrazinone and pyrimidine, as spacer and showing 
antiproliferative activity were synthesized [44–47]. 
Also, nortopsentins were considered lead compounds and several reports dealt with the synthesis  
and the evaluation of the antiproliferative activity of nortopsentin analogues bearing five-membered 
heterocycles, which replaced the imidazole ring of the natural product, such as bis-indolyl-thiophenes [48],  
-pyrazoles [49], -furans [50], -isoxazoles [50], -pyrroles [51], and -1,2,4-thiadiazoles [52]. Most of these 
analogues showed antiproliferative activity often reaching GI50 values at submicromolar level. 
Beside the eterocyclic spacer, the structural manipulation of the natural nortopsentins, was extended to 
one or both indole units and produced 3-[(2-indolyl)-5-phenyl]pyridine and phenylthiazolyl-7-azaindole 
derivatives, which showed antiproliferative activity and inhibited CDK1 [53,54]. 
More recently, due to the good results obtained by the aza-substitution of the indole moiety,  
3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-4-azaindole derivatives were synthesized and tested against 
breast cancer, prostate cancer, pancreatic carcinoma and peritoneal mesothelioma and showed cytotoxic 
activity, inhibited CDK1, and increased caspase-9 and caspase-3 activity (Chart 3) [55]. 
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Chart 3. Nortopsentin aza-analogues. 
Contemporaneously, 3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-7-azaindoles were synthesized and 
tested against the NCI full panel of human cancer cell lines and STO and MesoII cells, derived from human 
diffuse malignant peritoneal mesothelioma (DMPM). The most active compounds, which also act as CDK1 
inhibitors, administrated with paclitaxel produced a synergistic cytotoxic effect. In the mouse model, 
intraperitoneal (i.p.) administration of active derivatives was effective, resulting in a significant tumor 
volume inhibition of DMPM xenografts (range, 58%–75%) at well-tolerated doses, and two complete 
responses were observed in each treatment group [56]. 
Lately, two new series of nortopsentin analogues, 1 and 2, were efficiently synthesized and inhibited the 
growth of HCT-116 colorectal cancer cells at low micromolar concentrations, whereas they did not affect 
the viability of normal-like intestinal cells. A compound of the series 1 induced apoptosis. Instead, a 
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derivative of the series 2 at low concentrations (GI30) induced morphological changes characteristic of 
autophagic death with massive formation of cytoplasmic acid vacuoles without apparent loss of nuclear 
material, and with arrest of cell cycle at the G1 phase, whereas higher concentrations (GI70) induced 
apoptosis with arrest of cell cycle at the G1 phase [57]. 
In this paper, continuing our studies on indole and related azaindole systems [58–64], we report the 
synthesis of derivatives of type 3, nortopsentin analogues, in which indole and 7-azaindole units of the 
preceding very active 7-aza series were switched. We also report the antiproliferative activity of these new 
nortopsentin analogues and studies directed to elucidate their mode of action.  
2. Results and Discussion 
2.1. Chemistry 
Substituted 3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines of type 3 (Scheme 1, 
Table 1) were obtained by Hantzsch reaction between pyrrolo[2,3-b]pyridine-carbothioamides 6a,b and  
3-haloacetyl compounds 9a–d. 
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Scheme 1. Synthesis of substituted 3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-
b] pyridines 3a–k. Reagents: (i) (a) H2SO4, 25 °C, 15–60 min; (b) NaOH, 95%–99%;  
(ii) Lawesson’s reagent, THF, reflux, 30 min, 88%–99%; (iii) (a) t-BuOK, toluene,  
tris[2-(2-methoxyethoxy)ethyl]amine (TDA-1), 25 °C, 5–8 h; (b) MeI, 25 °C, 1–2 h,  
80%–98%; (iv) (a) NaH, THF, 0 °C–25 °C, 1–24 h; (b) p-TsCl, 25 °C, 4–24 h, 90%–96%; 
(v) AlCl3, CH2Cl2, ClCOCH2Cl, 1 h, 50%–55%; (vi) Br2, MeOH, reflux, 2 h, 40%, 70%; 
(vii) EtOH, reflux, 30 min, 30%–97%; (viii) KOH, EtOH, reflux, 1–2 h, 40%–98%. 
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The key intermediates 6a,b were obtained from the corresponding pyrrolo[2,3-b]pyridine-3-
carbonitriles 4a,b through the formation of carboxamides 5a,b, as previously reported [57]. 
N-protected 5-fluoroindoles 7b,c and 1-(1H-indol-3-yl)ethanones 8b,c were synthesized, in good  
yields (80%–98%), from commercially available 5-fluoroindole 7a or 1-(1H-indol-3-yl)ethanone 8a  
by methylation [54], or reaction with tosyl chloride using sodium hydride (NaH) as the base in  
tetrahydrofuran (THF). 
3-Haloacetyl indoles 9a–d were prepared from the corresponding indoles 7b,c or 1-(1H-indol-3-
yl)ethanones 8b,c. In particular, 3-chloroacetyl derivatives 9a,b were obtained by reaction of the 
corresponding N-methyl or N-tosyl 5-fluoroindole 7b,c with chloroacetyl chloride (ClCOCH2Cl) in the 
presence of aluminum chloride (AlCl3) in dichloromethane (CH2Cl2) in moderate yields (50%–55%); while 
3-bromoacetyl compounds 9c,d were synthesized (40%–70%) from the corresponding N-methyl or N-tosyl 
1-(1H-indol-3-yl)ethanone 8b,c using bromine in refluxing methanol (MeOH).  
Reaction between pyrrolo[2,3-b]pyridine-carbothioamides 6a,b and 3-haloacetyl compounds 9a–d in 
ethanol under reflux afforded the desired 3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines 
3a–h in moderate to excellent yields (30%–97%) (Table 1). 
The subsequent deprotection of N-tosyl derivatives 3e–h using potassium hydroxide in refluxing ethanol 
gave the corresponding compounds 3i–k (40%–98%). 
Table 1. Substituted 3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine 3a–k. 
Compound R R1 R2 Yield% Compound R R1 R2 Yield% 
3a H Me F 97 3g H Ts H 90 
3b Me Me F 30 3h Me Ts H 50 
3c H Me H 60 3i H H F 98 
3d Me Me H 60 3l Me H F 40 
3e H Ts F 97 3j H H H 98 
3f Me Ts F 40 3k Me H H 98 
2.2. Biology 
All the synthesized thiazoles 3a–k were evaluated by the National Cancer Institute (Bethesda MD) for 
cytotoxicity against the NCI-60 cell line panel using standard protocols [65]. Initially, the selected 
derivatives 3c,d,g,h,j,k were tested at a single dose (10−5 M) on the full panel of approximately 60 human 
tumor cell lines derived from 9 human cancer cell types, that have been grouped in disease  
sub-panels including leukemia, non-small-cell lung, colon, central nervous system (CNS), melanoma, 
ovarian, renal, prostate and breast cancers (data not shown). Compounds 3d and 3k were further selected 
for full evaluation at five concentration levels (10−4–10−8 M).  
The antitumor activity of compounds 3d and 3k was given by three parameters for each cell line: GI50 
(the molar concentration of the compound that inhibits 50% net cell growth), TGI (the molar concentration 
of the compound leading to total inhibition of net cell growth), and LC50 (the molar concentration of the 
compound that induces 50% net cell death). The average values of mean graph midpoint (MG_MID) were 
calculated for each of these parameters.  
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An evaluation of the data reported in Table 2 pointed out that compounds 3d and 3k exhibited 
antiproliferative activity against all the human cell lines at GI50 values from micromolar to nanomolar 
(13.0–0.03 and 14.2–0.04 µM, respectively). 
Table 2. In vitro inhibition of cancer cell line growth by indolyl-thiazolyl-pyrrolopyridines 3d, 3k a. 
Cell Lines GI50 (µM) Cell Lines GI50 (µM) Cell Lines GI50 (µM) 
 3d 3k  3d 3k  3d 3k 
Leukemia CNS Cancer Renal Cancer 
CCRF-CEM 0.40 0.43 SF-268 2.44 0.94 786-0 0.97 0.72 
HL-60(TB) 0.29 0.32 SF-295 0.24 0.31 A498 0.50 0.37 
K-562 0.07 0.12 SF-539 0.18 0.25 ACHN 0.72 0.51 
MOLT-4 0.67 0.66 SNB-19 0.63 0.64 CAKI-1 0.38 0.44 
RPMI-8226 0.45 0.65 SNB-75 0.16 0.14 RXF393 0.33 0.52 
SR 0.06 0.14 U251 0.41 0.43 SN12C 12.1 5.48 
      TK-10 0.60 0.99 
      UO-31 0.90 0.69 
Non-Small Cell Lung Cancer Melanoma Prostate Cancer 
A549/ATCC 0.56 0.71 LOX IMVI 0.54 0.51 PC-3 0.46 0.56 
EKVK 0.91 0.91 MALME-3M 1.04 0.74 DU-145 0.39 0.56 
HOP-62 0.81 0.93 M14 0.27 0.28    
HOP-92 0.35 0.31 MDA-MB-435 0.03 0.04    
NCI-H226 0.74 0.65 SK-MEL-2 0.58 0.41    
NCI-H23 0.72 0.67 SK-MEL-28 1.20 0.76  
NCI-H322M 0.76 ND b SK-MEL-5 0.24 0.27    
NCI-H460 0.30 0.37 UACC-257 13.0 14.2    
NCI-H522 0.04 0.05 UACC-62 0.30 0.42    
Colon Cancer Ovarian Cancer Breast Cancer 
COLO-205 0.19 0.19 IGROV1 1.33 1.18 MCF7 0.33 0.37 
HCC-2998 1.13 1.18 OVCAR-3 0.10 0.25 MDA-MB-231/ATCC 2.82 1.29 
HCT-116 0.37 0.39 OVCAR-4 7.22 0.52 HS 578T 0.59 0.66 
HCT-15 0.17 0.29 OVCAR-5 1.41 2.39 BT-549 0.47 0.44 
HT29 0.25 0.19 OVCAR-8 0.66 0.82 MDA-MB-468 0.28 0.23 
KM12 0.21 0.40 NCI/ADR-RES 0.09 0.15    
SW-620 0.22 0.30 SK-OV-3 0.57 0.52    
a Data obtained from NCI’s in vitro disease-oriented tumor cells screen; b ND = not determined. 
Indolyl-thiazolyl-pyrrolopyridine derivatives 3d and 3k were selective with respect to the leukemia 
cancer subpanel having all the subpanel cell lines GI50 in the range 0.06–0.67 μM and 0.12–0.66 μM, 
respectively. In particular, the most sensitive cell lines were K-562 (GI50 0.07 μM and 0.12 μM, 
respectively), and SR (GI50 0.06 μM and 0.14 μM, respectively). Derivatives 3d and 3k were also 
particularly sensitive against NCI-H522 (GI50 0.04 μM and 0.05 μM, respectively) of non-small cell lung 
cancer, NCI/ADR-RES (GI50 0.09 μM and 0.15 μM, respectively) of ovarian cancer, and  
MDA-MB-435 (GI50 0.03 μM and 0.04 μM, respectively) of melanoma subpanel. 
Cell growth inhibitory activity of 3d and 3k was also investigated on human HepG2 hepatocarcinoma. 
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Cell growth inhibitory activity of compounds 3d and 3k was also investigated on human HepG2 
hepatocarcinoma cells, a cell line not included in the NCI panel and of interest in the drug discovery 
because provided with a very active microsomal system for detoxification of xenobiotics. Monolayer 
cultures treated for 72 h with 0.1–10 μM concentrations of the compounds were examined by  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for cell growth. As shown in 
Figure 1, both the compounds inhibited the HepG2 cells growth in dose-dependent manner. Based on the 
dose response curve, the GI50 values were 1.69 µM) and 0.21 µM for 3d and 3k, respectively. Under 
identical conditions, both the nortopsentin analogues did not substantially impaired viability of normal 
immortalized human liver cells (Chang), suggesting high selectivity towards tumor cells. 
 
Figure 1. Effect 3d (A) and 3k (B) on the growth of HepG2 (black bars) or Chang cells 
(grey bars) as assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT). Cell monolayers were incubated for 24 h in the absence (control) or in the presence 
of the compounds at the indicated concentrations and cell growth was assessed by MTT 
test as reported Methods. Results are indicated as the percentage of viable cells with 
respect to untreated controls. Values are the mean ± SD of three separate experiments 
carried out in triplicate. 
The distribution of HepG2 cells in the cell cycle phases after 24 h treatment with the two norptopsentin 
analogues, was assessed by flow cytometric analysis after staining of DNA with PI. Both compounds 3d 
and 3k caused a significant dose-dependent decrease in the percentage of cells in the G0/G1 and S phases, 
accompanied by a concomitant percentage increase of cells in the G2/M phase, and appearance of a  
subG1-cell population (Figure 2).  
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Figure 2. Effect of 3d and 3k on the cell cycle distribution of human hepatoma HepG2 
cells. Flow cytometric analysis of propidium iodide (PI)-stained cells, as determined by 
flow cytometry after 24 h treatment with the compounds or vehicle alone (control). The 
percentage of cells in the different phases of the cycle was calculated by Expo32 software. 
Values are the mean ± SD of three separate experiments in triplicate. 
 
Figure 3. Apoptosis induced by 3d an 3k nortopsentin analogues in HepG2 cells. (A) 
Percentage of Annexin V/propidium iodide (PI) double-stained cells, as determined by 
flow cytometry; (B) Fluorescence micrographs of ethidium bromide/acridine orange 
double-stained cells. Control, cells treated with vehicle; 3d and 3k, cells treated for 24 h 
with either Nortopsentin derivative at GI50 concentration. (A) Representative images of 
three experiments with comparable results; (B) Representative images, in 200 × magnification, 
of three experiments with comparable results.  
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Apoptosis induction by 3d and 3k in HepG2 cells was investigated by externalization of plasma 
membrane phosphatidylserine and changes of mitochondrial transmembrane potential. Flow cytometry 
analysis of Annexin V-FITC/PI-stained cells after 24 h treatment with the Norptopsentin analogues, 
assayed at their relevant GI50 values, indicated a high percentage of cells in early apoptosis, with 
externalized phosphatidylserine (Figure 3A).  
To confirm apoptotic mechanism of cytotoxicity of the nortopsentin analogues, we carried out 
morphological evaluation of HepG2 cells using AO and EB double staining. After 24 h of treatment with 
3d or 3k at GI50 concentration, fluorescent microscopy revealed the appearance of cells containing bright 
green patches in the nuclei as a consequence of chromatin condensation and nuclear fragmentation, which 
are typical features of apoptosis. Moreover, fluorescing orange cells owing to increase of cell permeability 
to ethidium bromide, cell shrinkage and nuclear fragmentation were also evident as cells in late apoptosis 
(Figure 3B). Taken together, these findings provided strong evidence that the synthesized nortopsentin 
analogues induced apoptosis in HepG2 cells. 
 
Figure 4. Mitochondrial dysfunction induced by 3d and 3k in HepG2 cells. (A) Fluorescence 
intensity of 3,30-dihexyloxacarbocyanine iodide-treated cells, as determined by flow 
cytometry; (B) Fluorescence intensity of 2′,7′-dichlorofluorescin diacetate-stained cells, as 
determined by flow cytometry. Control, cells treated with vehicle; 3d and 3k, cells treated 
for 24 h with either Nortopsentin derivative at GI50 concentration. Representative images of 
three experiments with comparable results. 
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Involvement of mitochondria in apoptosis induced in HepG2 cells by the synthesized nortopsentin 
analogues, was assessed. Loss of mitochondrial trans-membrane potential was indicated by decreased 
mitochondrial 3,30-dihexyloxacarbocyanine iodide-red fluorescence (Figure 4A). Mitochondrial 
dysfunction in HepG2 cells following 24 h treatment with 3d and 3k, was also evident from the levels of 
intracellular ROS, revealed by cytofluorimetric analysis with 2′,7′-dichlorofluorescin diacetate, significantly 
higher than cell control (Figure 4B).  
3. Experimental Section 
3.1. Chemistry 
3.1.1. General 
All melting points were taken on a Büchi-Tottoly capillary apparatus. IR spectra were determined in 
bromoform with a Shimadzu FT/IR 8400S spectrophotometer. 1H and 13C NMR spectra were measured at 
200 and 50.0 MHz, respectively, in dimethylsulfoxide (DMSO)-d6 or CDCl3 solution, using a Bruker 
Avance II series 200 MHz spectrometer. Compounds 3a,b were characterized only by 1H NMR spectra 
because of their poor solubility. Column chromatography was performed with Merk silica gel 230–400 
mesh ASTM or with Büchi Sepacor chromatography module (prepacked cartridge system). Elemental 
analyses (C, H, N) were within ±0.4% of theoretical values and were performed with a VARIO EL III 
elemental analyzer. Purity of all the tested compounds was greater than 98%, determined by HPLC as 
described below. 
3.1.2. Synthesis of 5-Fluoro-1-methyl-1H-indole (7b) 
To a cold solution of 5-fluoroindole 7a (0.8 g, 5.0 mmol) in anhydrous toluene (50 mL), potassium  
t-butoxide (0.8 g, 6.8 mmol) and tris[2-(2-methoxyethoxy)ethyl]amine (TDA-1) (1–2 drops) were added. 
The reaction mixture was stirred at room temperature for 5 h and then methyl iodide (0.3 mL,  
5 mmol) was added. TLC analysis (dichloromethane (DCM)/petroleum ether (9/1) revealed that 
methylation was complete after 1 h. The solvent was evaporated under reduced pressure and the residue, 
treated with water (15 mL), was extracted with DCM (3 × 15 mL), dried (Na2SO4) and evaporated to afford 
the pure methyl derivative 7b. 
Yellow solid; yield: 98%; mp: 55–56 °C. Analytical and spectroscopic data were in agreement with 
those previously reported [50]. 
3.1.3. Synthesis of 5-Fluoro-1-[(4-methylphenyl)sulfonyl]-1H-indole (7c) 
To a stirred solution of 5-fluoroindole 7a (1.0 g, 7.4 mmol) in tetrahydrofuran (THF) (5.0 mL) sodium 
hydride (60% dispersion in mineral oil, 0.4 g, 9.6 mmol) was added at 0 °C and the mixture was stirred at 
room temperature for 24 h. p-Toluenesulfonyl chloride (2.1 g, 11.1 mmol) was added to the reaction and 
the mixture was stirred at room temperature for 4 h. The residue was evaporated under reduced pressure, 
treated with water (20 mL) and extracted with ethyl acetate (EtOAc) (3 × 20 mL). The organic phase was 
dried (Na2SO4), evaporated under reduced pressure and purified by column chromatography using 
petroleum ether/DCM (9/1) as eluent. White solid; yield: 96%; mp: 111–112 °C; IR 1373,  
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1172 (SO2) cm−1; 1H NMR (200 MHz, DMSO-d6) δ: 2.32 (s, 3H, CH3), 6.82–6.84 (m, 1H,  
H-7), 7.19 (td, 1H, J = 2.6, 9.2, 11.0 Hz, H-6), 7.39 (d, 2H, J = 8.7 Hz, H-3′, H-5′), 7.45 (d, 1H,  
J = 2.6 Hz, H-3), 7.87 (d, 2H, J = 8.7 Hz, H-2′, H-6′), 7.88–7.97 (m, 2H, H-2, H-4); 13C NMR  
(50 MHz, DMSO-d6) δ: 21.0 (q), 107.0 (d, JC4–F = 24.1 Hz), 109.3 (d, JC3–F = 4.2 Hz), 112.5 (d,  
JC6–F = 25.8 Hz), 114.4 (d, JC7–F = 9.6 Hz), 126.7 (2xd), 128.9 (d), 130.2 (2xd), 130.6 (s), 131.6 (d,  
JC3a–F = 10.4 Hz), 133.9 (s), 145.6 (s), 158.9 (d, JC5–F = 237.7 Hz). Anal. Calcd for: C15H12FNO2S: C, 
62.27; H, 4.18; N, 4.84. Found: C, 62.57; H, 4.38; N, 4.69. 
3.1.4. Synthesis of 1-(1-Methyl-1H-indol-3-yl)ethanone (8b)  
To a cold solution of 3-acetylindole 8a (1.0 g, 6.3 mmol) in anhydrous toluene (50 mL), potassium  
t-butoxide (1.0 g, 8.6 mmol) and TDA-1 (1–2 drops) were added. The reaction mixture was stirred at room 
temperature for 8 h and then methyl iodide (0.4 mL, 6.3 mmol) was added. TLC analysis (DCM/EtOAc 
9/1) revealed that methylation was complete after 2 h. The solvent was evaporated under reduced pressure. 
The residue was treated with water (50 mL), extracted with DCM (3 × 50 mL), dried (Na2SO4), 
evaporated under reduced pressure, and purified by column chromatography using DCM/EtOAc (9/1)  
as eluent. 
White solid; yield 80%; mp: 108–109 °C. Analytical and spectroscopic data were in agreement with 
those previously reported [48]. 
3.1.5. Synthesis of 1-{1-[(4-Methylphenyl)sulfonyl]-1H-indol-3-yl}ethanone (8c) 
To a solution of 3-acetylindole 8a (1.0 g, 6.3 mmol) in THF (5.0 mL) sodium hydride (60% dispersion 
in mineral oil, 0.3 g, 6.3 mmol) was added at 0 °C and the mixture was stirred at room temperature for 1 h. 
p-toluenesulfonyl chloride (1.2 g, 6.3 mmol) was added and the mixture was stirred at room temperature 
for 24 h. The residue was evaporated under reduced pressure, treated with water (20 mL) and extracted 
with EtOAc (3 × 20 mL). The organic phase was dried (Na2SO4), evaporated under reduced pressure and 
purified by column chromatography using DCM as eluent. White solid; yield: 90%; mp: 148–149 °C; IR 
1662 (CO), 1382, 1299 (SO2) cm−1; 1H NMR (200 MHz, DMSO-d6) δ: 2.33 (s, 3H, CH3), 2.60 (s, 3H, 
CH3), 7.32–7.39 (m, 2H, H-5, H-6), 7.43 (d, 2H, J = 7.8 Hz, H-3′, H-5′), 7.95 (d, 1H, J = 7.5 Hz, H-7), 8.04 
(d, 2H, J = 7.8 Hz, H-2′, H-6′), 8.19 (d, 1H, J = 7.5 Hz, H-4), 8.81 (s, 1H, H-2); 13C NMR (50 MHz, 
DMSO-d6) δ:21.0 (q), 27.8 (q), 113.0 (d), 120.7 (s), 122.3 (d), 124.8 (d), 125.6 (d), 127.0 (s), 127.2 (2xd), 
130.5 (2xd), 133.5 (s), 134.0 (s), 134.2 (d), 146.2 (s), 193.9 (s). Anal. Calcd for: C17H15NO3S: C, 65.16; H, 
4.82; N, 4.47. Found: C, 65.28, H, 5.06, N, 4.37. 
3.1.6. Synthesis of 2-Chloro-1-(5-fluoro-1H-indol-3-yl)ethanones (9a,b) 
To a stirred suspension of anhydrous aluminium chloride (1.1 g, 8.5 mmol), in DCM (18.0 mL), was 
added dropwise at 0 °C a solution of the suitable indole 7b,c (1.2 mmol) in DCM (5.0 mL) under nitrogen 
atmosphere. Then, chloroacetyl chloride (0.3 mL, 3.6 mmol) was slowly added to the reaction mixture, 
which was stirred at room temperature for 1 h and then poured in ice and water (20 mL) and extracted with 
DCM (3 × 20 mL). The organic phase was dried (Na2SO4), evaporated under reduced pressure and purified 
by column chromatography using DCM as eluent. 
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3.1.6.1. 2-Chloro-1-(5-fluoro-1-methyl-1H-indol-3-yl)ethanone (9a) 
White solid; yield: 50%; mp: 185–186 °C; IR 1653 (CO) cm−1; 1H NMR (200 MHz, DMSO-d6) δ: 3.89 
(s, 3H, CH3), 4.84 (s, 2H, CH2), 7.20 (td, 1H, J = 2.6, 9.2, 11.0 Hz, H-6), 7.62 (dd, 1H, J = 4.5, 9.2 Hz,  
H-7), 7.84 (dd, 1H, J = 2.6, 11.0 Hz, H-4), 8.51 (bs, 1H, H-2);13C NMR (50 MHz, DMSO-d6) δ: 33.7 (q), 
46.2 (t), 106.1 (d, JC4–F = 24.8 Hz), 111.3 (d, JC6–F = 26.1 Hz), 112.3 (s), 112.4 (d, JC7–F = 9.8 Hz), 126.4 (d, 
JC3a–F = 11.0 Hz), 133.9 (s), 139.5 (d), 159.0 (d, JC5–F = 236 Hz), 185.6 (s). Anal. Calcd for C11H9ClFNO: 
C, 58.55; H, 4.02; N, 6.21. Found: C, 58.85; H, 4.14; N, 6.01. 
3.1.6.2. 2-Chloro-1-{5-fluoro-1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}ethanone (9b) 
White solid; yield: 55%; mp: 155–156 °C; IR 1683 (CO), 1375, 1171 (SO2) cm−1; 1H NMR (200 MHz, 
CDCl3) δ: 2.39 (s, 3H, CH3), 4.54 (s, 2H, CH2), 7.13 (td, 1H, J = 2.6, 8.9, 11.0 Hz, H-6), 7.31 (d, 2H,  
J = 8.0 Hz, H-3′, H-5′), 7.82 (d, 2H, J = 8.0 Hz, H-2′, H-6′), 7.90 (dd, 1H, J = 4.9, 8.9 Hz, H-7), 7.98 (dd, 
2H, J = 2.6, 11.0 Hz, H-4), 8.34 (s, 1H, H-2); 13C NMR (50 MHz, CDCl3) δ: 21.7 (q), 45.8 (t), 108.9 (d, 
JC6–F = 25.5 Hz), 114.1 (s), 114.2 (d), 114.5 (d, JC4–F = 14.0 Hz), 117.9 (s, JC7a–F = 4.5 Hz), 127.2 (2xd), 
130.2 (s), 130.4 (2xd), 133.5 (d), 134.1 (s), 146.5 (s), 160.1 (s, JC5–F = 241 Hz), 186.7 (s). Anal. Calcd for 
C17H13ClFNO3S: C, 55.82; H, 3.58; N, 3.83. Found: C, 55.99; H, 3.36; N, 4.10. 
3.1.7. Synthesis of 2-Bromo-(1H-indol-3-yl)ethanones (9c,d) 
To a cold suspension of the appropriate 3-acetylindole 8b,c (1.9 mmol) in anhydrous methanol  
(3.0 mL) bromine (0.1 mL, 1.9 mmol) was added dropwise. The mixture was heated at reflux for 2 h. After 
cooling the solvent was evaporated under reduced pressure. The residue was treated with water (20 mL), 
made alkaline by adding sodium hydrogen carbonate (150 mg) and extracted with EtOAc (3 × 50 mL). The 
organic phase was dried (Na2SO4), evaporated under reduced pressure and purified by column 
chromatography using DCM as eluent. 
3.1.7.1. 2-Bromo-1-(1-methyl-1H-indol-3-yl)ethanone (9c) 
Brown solid; yield: 70%; mp: 205–206 °C. Analytical and spectroscopic data were in agreement with 
those previously reported [48]. 
3.1.7.2. 2-Bromo-1-{1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}ethanone (9d) 
Brown solid; yield: 40%; mp: 134–135 °C; IR 1668 (CO), 1379, 1177 (SO2) cm−1; 1H NMR (200 MHz, 
CDCl3) δ: 2.38 (s, 3H, CH3), 4.36 (s, 2H, CH2), 7.29 (d, 2H, J = 8.2 Hz, H-3′, H-5′), 7.36–7.40 (m, 2H,  
H-5, H-6), 7.83–7.87 (m, 2H, H-2′, H-6′), 7.91–7.96 (m, 1H, H-7), 8.28–8.34 (m, 2H, H-2, H-4); 13C NMR 
(50 MHz, CDCl3) δ: 21.7 (q), 31.4 (t), 113.1 (d), 123.1 (d), 124.3 (s), 125.1 (d), 126.1 (d), 127.2 (2xd), 
127.5 (s), 130.4 (2xd), 132.8 (d), 134.2 (s), 134.8 (s), 146.2 (s), 187.0 (s). Anal. Calcd. for: C17H14BrNO3S: 
C, 52.05; H, 3.60; N, 3.57. Found: C, 52.25; H, 3.70; N, 3.35. 
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3.1.8. Synthesis of 3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines (3a–h) 
A suspension of the appropriate pyrrolo[2,3-b]pyridine-carbothioamide 6a,b (5.0 mmol) and  
halo-acetyl compounds 9a–d (5.0 mmol) in ethanol (3.0 mL) was heated under reflux for 30 min. The 
precipitate, obtained after cooling, was filtered off, dried and recrystallized from ethanol to afford 
derivatives 3a–h. 
3.1.8.1. 3-[4-(5-Fluoro-1-methyl-1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine (3a) 
Yellow solid; yield: 97%; mp: 237–238 °C; IR 3550 (NH) cm−1; 1H NMR (200 MHz, DMSO-d6) δ: 
3.90 (s, 3H, CH3), 7.12 (t, 1H, J = 8.2 Hz, H-6″), 7.44 (dd, 1H, J = 5.2, 7.4 Hz, H-5′), 7.54 (dd, 1H,  
J = 4.6, 8.2 Hz, H-7″), 7.73 (s, 1H, H-2″), 7.94 (dd, 1H, J = 9.7, 2.5 Hz, H-4″), 8.16 (bs, 1H, H-2′), 8.38 (s, 
1H, H-5), 8.45 (d, 1H, J = 3.7 Hz, H-6′), 8.89 (d, 1H, J = 7.4 Hz, H-4′), 12.74 (bs, 1H, NH). Anal. Calcd for 
C19H13FN4S: C, 65.50; H, 3.76; N, 16.08. Found: C, 65.76; H, 3.55; N, 16.22. 
3.1.8.2. 3-[4-(5-Fluoro-1-methyl-1H-indol-3-yl)-1,3-thiazol-2-yl]-1-methyl-1H-pyrrolo[2,3-b]pyridine (3b)  
Yellow solid; yield: 30%; mp: 286–287 °C; 1H NMR (200 MHz, DMSO-d6) δ: 2.56 (s, 3H, CH3), 4.03 
(s, 3H, CH3), 6.02 (dd, 1H, J = 4.3, 10.7 Hz, H-7″), 6.76 (td, 1H, J = 2.3, 9.5, 10.7 Hz, H-6″), 6.98 (dd, 1H, 
J = 5.0, 8.4 Hz, H-5′), 7.25 (dd, 1H, J = 2.3, 9.5 Hz, H-4″), 7.72 (d, 1H, J = 8.4 Hz,  
H-4′), 8.19-8.81 (m, 4H, H-2’, H-2’’, H-5, H-6′). Anal. Calcd for C20H15FN4S: C, 66.28; H, 4.17; N, 15.46. 
Found: C, 66.53; H, 3.90; N, 15.23. 
3.1.8.3. 3-[4-(1-Methyl-1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine (3c) 
Yellow solid; yield: 60%; mp: 274–275 °C, IR 3427 (NH) cm−1; 1H NMR (200 MHz, DMSO-d6) δ: 
3.90 (s, 3H, CH3), 7.21–7.30 (m, 2H, H-5″, H-6″), 7.36 (dd, 1H, J = 4.9, 7.7 Hz, H-5′), 7.53 (d, 1H,  
J = 7.1 Hz, H-7″), 7.66 (s, 1H, H-2″), 8.05 (s, 1H, H-5), 8.19 (d, 1H, J = 7.1 Hz, H-4″), 8.30 (d, 1H,  
J = 2.0 Hz, H-2′), 8.40 (d, 1H, J = 4.9 Hz, H-6′), 8.79 (d, 1H, J = 7.7 Hz, H-4′), 12.40 (bs, 1H, NH); 13C 
NMR (50 MHz, DMSO-d6) δ: 32.6 (q), 106.5 (d), 109.6 (s), 110.2 (d), 117.1 (d), 117.3 (s), 119.9 (d), 120.1 
(d), 121.6 (d), 124.9 (s), 126.9 (d), 129.2 (d), 129.7 (d), 137.1 (s), 143.2 (d), 143.3 (s), 147.9 (s), 150.1 (s), 
161.0 (s). Anal. Calcd for C19H14N4S: C, 69.07; H, 4.27; N, 16.96. Found: C, 68.90; H, 4.46; N, 16.75. 
3.1.8.4. 1-Methyl-3-[4-(1-methyl-1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine (3d) 
Yellow solid; yield: 60%; mp: 290–291 °C; 1H NMR (200 MHz, DMSO-d6) δ: 3.90 (s, 3H, CH3), 3.94 
(s, 3H, CH3), 7.17–7.30 (m, 2H, H-5″, H-6″), 7.39 (dd, 1H, J = 4.7, 7.9 Hz, H-5′), 7.53 (dd, 1H,  
J = 1.4, 6.9 Hz, H-7″), 7.66 (s, 1H, H-2″), 8.05 (s, 1H, H-2′), 8.19 (dd, 1H, J = 1.4, 6.9 Hz, H-4″), 8.41 (s, 
1H, H-5), 8.45 (dd, 1H, J = 1.3, 4.7 Hz, H-6′), 8.78 (dd, 1H, J = 1.3, 7.9 Hz, H-4′); 13C NMR (50 MHz, 
DMSO-d6) δ: 31.4 (q), 32.6 (q), 106.5 (d), 108.3 (s), 110.0 (s), 110.2 (d), 117.2 (d), 117.5 (s), 119.9 (d), 
120.1 (d), 121.6 (d), 124.9 (s), 129.3 (d), 129.8 (d), 130.5 (d), 137.0 (s), 143.1 (d), 147.0 (s), 150.1 (s), 
160.7 (s). Anal. Calcd for C20H16N4S: C, 69.74; H, 4.68; N, 16.27. Found: C, 69.50; H, 4.84; N, 16.06. 
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3.1.8.5. 3-(4-{5-Fluoro-1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}-1,3-thiazol-2-yl)-1H-pyrrolo 
[2,3-b]pyridine (3e) 
Yellow solid; yield: 97%; mp: 257–258 °C; IR 3337 (NH), 1370, 1171 (SO2); 1H NMR (200 MHz, 
DMSO-d6) δ: 2.31 (s, 3H, CH3), 7.28–7.32 (m, 2H, ArH), 7.39–7.42 (m, 2H, H-3‴, H-5‴), 7.94–7.98 (m, 
2H, H-2‴, H-6‴), 8.03–8.15 (m, 3H, ArH), 8.42–8.49 (m, 3H, ArH), 8.74 (d, 1H, J = 7.4 Hz,  
H-4′), 12.67 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 21.1 (q), 107.3 (d, JC4″–F = 24.1 Hz), 109.3 (s), 
112.6 (d, JC6″–F = 26.8 Hz), 113.4 (d), 114.9 (d, JC7″–F = 9.9 Hz), 117.2 (d), 117.4 (s), 117.5 (s), 117.6 (s), 
126.3 (d), 126.9 (2xd), 127.8 (d), 128.8 (s), 129.0 (s), 130.2 (d), 130.4 (2xd), 131.1 (s), 133.6 (s), 142.3 (d), 
145.9 (s), 146.9 (s), 159.4 (d, JC5″–F = 245.5 Hz). Anal. Calcd. for C25H17FN4O2S2: C, 61.46; H, 3.51; N, 
11.47. Found: C, 61.73; H, 3.25; N, 11.31. 
3.1.8.6. 3-(4-{5-Fluoro-1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}-1,3-thiazol-2-yl)-1-methyl-1H-
pyrrolo[2,3-b]pyridine (3f)  
White solid; yield: 40%; mp: 230–231 °C; IR 1380, 1299 (SO2) cm−1; 1H NMR (200 MHz, DMSO-d6) 
δ: 2.32 (s, 3H, CH3), 3.94 (s, 3H, CH3), 7.28–7.43 (m, 2H, ArH), 7.41 (d, 2H, J = 7.8 Hz, H-3‴,  
H-5‴), 7.87–7.94 (m, 2H, H-2‴, H-6‴), 7.99–8.13 (m, 3H, ArH), 8.42–8.48 (m, 3H, ArH), 8.60 (d, 1H,  
J = 7.3 Hz, H-4′); 13C NMR (50 MHz, DMSO-d6) δ: 21.0 (q), 31.2 (q), 107.4 (d, JC4″–F = 25.2 Hz), 107.8 
(s), 112.0 (d), 113.1 (d, JC6″–F = 27.5 Hz), 114.8 (d, JC7″–F = 9.1 Hz), 116.9 (s), 117.4 (d), 117.5 (d,  
JC7″–a = 4.0 Hz), 126.3 (d), 126.9 (2xd), 128.6 (d), 128.8 (s), 129.0 (s), 130.4 (s), 130.8 (2xd), 131.1 (s), 
133.6 (s), 143.8 (d), 145.9 (s), 146.9 (s), 147.6 (s), 159.3 (d, JC5″–F = 246.5 Hz). Anal. Calcd. for 
C26H19FN4O2S2: C, 62.13; H, 3.81; N, 11.15. Found: C, 61.98; H, 3.99; N, 10.90. 
3.1.8.7. 3-(4-{1-[(4-Methylphenyl)sulfonyl]-1H-indol-3-yl}-1,3-thiazol-2-yl)-1H-pyrrolo[2,3-b] 
pyridine (3g) 
Yellow solid; yield: 90%; mp: 260–261 °C; IR 3498 (NH), 1374, 1174 (SO2) cm−1; 1H NMR  
(200 MHz, DMSO-d6) δ: 2.30 (s, 3H, CH3), 7.31–7.41 (m, 5H, ArH), 7.94–7.98 (m, 2H, ArH),  
8.01–8.07 (m, 2H, ArH), 8.36–8.39 (m, 4H, ArH), 8.64 (d, 1H, J = 7.7 Hz, H-4′), 12.39 (bs, 1H, NH);13C 
NMR (50 MHz, DMSO-d6) δ: 21.0 (q), 109.1 (s), 111.8 (d), 113.4 (d), 116.7 (s), 117.2 (d), 117.7 (s), 121.7 
(d), 124.0 (d), 124.5 (d), 125.2 (d), 126.8 (2xd), 127.2 (d), 127.9 (s), 128.6 (d), 130.3 (2xd), 133.8 (s), 134.6 
(s), 144.0 (d), 145.7 (s), 147.3 (s), 148.7 (s), 162.1 (s). Anal. Calcd. for C25H18N4O2S2: C, 63.81; H, 3.86; 
N, 11.91. Found: C, 63.55; H, 4.02; N, 11.76.  
3.1.8.8. 1-Methyl-3-(4-{1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}-1,3-thiazol-2-yl)-1H-pyrrolo 
[2,3-b]pyridine (3h) 
Yellow solid; yield: 50%; mp: 250–251 °C; IR 1374, 1174 (SO2) cm−1; 1H NMR (200 MHz, DMSO-d6) 
δ: 2.30 (s, 3H, CH3), 3.94 (s, 3H, CH3), 7.37–7.45 (m, 5H, ArH), 7.93–7.97 (m, 2H, ArH), 8.01–8.09 (m, 
2H, ArH), 8.31–8.47 (m, 4H, ArH), 8.66 (d, 1H, J = 7.5 Hz, H-4′);13C NMR (50 MHz, DMSO-d6) δ: 21.0 
(q), 31.4 (q), 108.0 (s), 112.0 (d), 113.4 (d), 117.2 (s), 117.4 (d), 117.6 (s), 121.7 (d), 124.0 (d), 124.6 (d), 
125.2 (d), 126.8 (2xd), 127.8 (s), 129.3 (d), 130.3 (2xd), 130.9 (d), 133.8 (s), 134.6 (s), 145.7 (s), 147.1 (s), 
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147.4 (s), 148.2 (d), 161.6 (s). Anal. Calcd for: C26H20N4O2S2: C, 64.44; H, 4.16, N, 11.56. Found: C, 
64.19; H, 4.33; N, 11.25. 
3.1.9. Synthesis of 3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines (3i–k) 
To a suspension of derivatives 3e–h (0.6 mmol) in ethanol (2 mL), potassium hydroxide (0.1 g,  
1.8 mmol) was added and the mixture was heated at reflux for 1–2 h. The precipitate, obtained after 
cooling, was filtered off, dried and recrystallized from ethanol to afford derivatives 3i–k. 
3.1.9.1. 3-[4-(5-Fluoro-1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine (3i) 
Conditions: reflux for 1.5 h. Yellow solid; yield: 98%; mp: 248–249 °C; IR 3600 and 3550(2xNH), 
cm−1; 1H NMR (200 MHz, DMSO-d6) δ: 7.05 (t, 1H, J = 7.8 Hz, H-6″), 7.47–7.53 (m, 2H, H-5′,  
H-7″), 7.78 (bs, 1H, H-2″), 7.92 (d, 1H, J = 8.9 Hz, H-4″), 8.19 (bs, 1H, H-2′), 8.47 (m, 2H, H-5,  
H-6′), 8.95 (d, 1H, J = 7.4 Hz, H-4′), 11.70 (bs, 1H, NH), 12.93 (bs, 1H, NH); 13C NMR (50 MHz,  
DMSO-d6) δ: 104.7 (d, JC4″–F = 21.6 Hz), 107.3 (d), 109.7 (d, JC6″–F = 26.1 Hz), 109.8 (s), 110.7 (s), 113.0 
(d, JC7″–F = 10.0 Hz), 117.2 (d), 119.0 (s), 124.6 (d, JC3″–F = 10.5 Hz), 127.2 (d), 128.2 (d), 132.3 (d), 133.3 
(s), 140.6 (d), 144.7 (s), 149.6 (s), 157.5 (d, JC5″–F = 232 Hz), 160.5 (s). Anal. Calcd. for C18H11FN4S: C, 
64.66; H, 3.32; N, 16.76. Found: C, 64.37; H, 3.04; N, 16.57. 
3.1.9.2. 3-[4-(5-Fluoro-1H-indol-3-yl)-1,3-thiazol-2-yl]-1-methyl-1H-pyrrolo[2,3-b]pyridine (3l)  
Conditions: reflux for 1 h. Yellow solid; yield 40%; mp: 243–244 °C; IR 3557 (NH) cm−1; 1H NMR 
(200 MHz, DMSO-d6) δ: 3.93 (s, 3H, CH3), 7.04 (td, 1H, J = 2.1, 9.1, 10.9 Hz, H-6″), 7.35 (dd, 1H,  
J = 4.6, 7.8 Hz, H-5′), 7.49 (dd, 1H, J = 4.6, 9.1 Hz, H-7″), 7.70 (s, 1H, H-2″), 7.96 (dd, 1H, J = 2.1, 10.9 
Hz, H-4″), 8.11 (bs, 1H, H-2′), 8.38 (s, 1H, H-5), 8.42 (d, 1H, J = 4.6 Hz, H-6′), 8.69 (d, 1H,  
J = 7.8 Hz, H-4′), 11.64 (bs, 1H, NH);13C NMR (50 MHz, DMSO-d6) δ: 31.2 (q), 104.9 (d,  
JC4″–F = 24 Hz), 106.5 (d), 108.3 (s), 109.7 (d, JC6″–F = 26 Hz), 111.3 (d, JC7″–F = 4.5 Hz), 112.9 (d,  
JC7″–F = 9.5 Hz), 117.0 (s), 117.2 (d), 124.8 (d, JC4″–F = 10.1 Hz), 126.8 (d), 129.0 (d), 130.2 (d), 133.3 (s), 
143.7 (d), 147.6 (s), 150.2 (s), 157.4 (d, JC5″–F = 231.9 Hz), 160.8 (s). Anal. Calcd. for C19H13FN4S: C, 
65.50; H, 3.76; N, 16.08. Found: C, 65.36; H, 3.47; N, 15.82. 
3.1.9.3. 3-[4-(1H-Indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine (3j) 
Conditions: reflux for 2 h. Yellow solid; yield: 98%; mp: 297–298 °C; IR 3676 and 3557 (2xNH) cm−1; 
1H NMR (200 MHz, DMSO-d6) δ: 7.13–7.23 (m, 2H, H-5″, H-6″), 7.39 (dd, 1H, J = 4.9, 7.9 Hz,  
H-5′), 7.47–7.51 (m, 1H, H-7″), 7.68 (bs, 1H, H-2″), 8.05 (d, 1H, J = 2.6 Hz, H-2′), 8.18 (dd, 1H,  
J = 2.7, 7.1 Hz, H-4″), 8.34 (s, 1H, H-5), 8.42 (dd, 1H, J = 1.5, 4.9 Hz, H-6′), 8.82 (dd, 1H, J = 1.5, 7.9 Hz, 
H-4′), 11.46 (bs, 1H, NH), 12.50 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 106.6 (d), 109.7 (s), 
110.9 (s), 111.9 (d), 117.1 (d), 117.6 (s), 119.8 (d), 120.0 (d), 121.5 (d), 124.6 (s), 125.1 (d), 127.1 (d), 
130.3 (d), 136.6 (s), 142.7 (d), 147.3 (s), 150.5 (s), 160.8 (s). Anal. Calcd for C18H12N4S: C, 68.33; H, 3.82; 
N, 17.71. Found: C, 68.06; H, 4.07; N, 17.45. 
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3.1.9.4. 3-[4-(1H-Indol-3-yl)-1,3-thiazol-2-yl]-1-methyl-1H-pyrrolo[2,3-b]pyridine (3k) 
Conditions: reflux for 1.5 h. Yellow solid; yield: 98%; mp: 276–277 °C; IR 3500 (NH) cm−1; 1H NMR 
(200 MHz, DMSO-d6) δ: 3.95 (s, 3H, CH3), 7.14–7.25 (m, 2H, H-5″, H-6″), 7.41 (dd, 1H,  
J = 5.0, 7.7 Hz, H-5′), 7.50 (dd, 1H, J = 2.1, 7.4 Hz, H-7″), 7.69 (bs, 1H, H-2″), 8.05 (d, 1H, J = 5.0 Hz, 
H-6′), 8.16–8.21 (m, 1H, H-4″), 8.45–8.48 (m, 2H, H-5, H-2′), 8.78 (dd, 1H, J = 2.0, 7.7 Hz, H-4′), 11.49 
(s, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 31.6 (q), 106.8 (d), 108.4 (s), 110.7 (s), 111.9 (d), 117.3 (d), 
119.8 (d), 119.9 (d), 121.6 (d), 124.6 (s), 125.1 (d), 125.9 (s), 130.3 (d), 130.8 (d), 135.7 (s), 136.6 (s), 
142.6 (d), 150.3 (s), 160.6 (s). Anal. Calcd for C19H14N4S: C, 69.07; H, 4.27; N, 16.96. Found: C, 69.31; H, 
4.50; N, 16.70. 
3.2. HPLC Analysis 
Analysis of nortopsentin analogues was carried out using a Gilson modular liquid chromatography 
system (Gilson Inc., Middleton, WI, USA) equipped with M 302 and 305 pumps, and injector model 77–25 
(Rheodyne, Berkeley, CA, USA) with a 20 μL injector loop and a M 802 manometric module. The 
chromatographic column was a µPorasil column (300 × 3.9 mm; Waters, Milford, MA, USA) provided 
with relevant guard cartridge (5 × 3.9 mm, Waters). Detection at 283 nm was by an M 118 UV-vis detector, 
used along with the Gilson 712 HPLC system controller software. Sensitivity was 0.05% absorbance unit 
(AUFS). Elution was with a 20 min linear gradient elution from solvent A (dichlomethane:ethyl acetate, 
1:1) to 100% solvent B (ethyl acetate), at a flow rate of 1 mL/min. Retention times of 3d and 3k were  
8.10 min and 8.33 min, respectively. 
3.3. Biology 
3.3.1. Viability Assay in Vitro  
The tested compounds 3d and 3k were dissolved in DMSO and then diluted in culture medium so that 
the effective DMSO concentration did not exceed 0.1%. Human cell lines of hepatoma HepG2 and Chang 
liver were purchased from American Type Culture Collection, Rockville, MD, USA. Cells were grown in 
RPMI supplemented with 2 mM L-glutamine, 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin 
and 5 μg/mL gentamicin. HepG2 culture medium also contained 1.0 mM sodium pyruvate. Cells were 
maintained in log phase by seeding twice a week at a density of 3 × 108 cells/L in humidified 5% CO2 
atmosphere, at 37 °C. In all experiments, cells were made quiescent through overnight incubation before 
the treatment with the compounds or vehicle alone (control cells). No differences were found between cells 
treated with DMSO 0.1% and untreated cells in terms of cell number and viability. Cytotoxic activity of the 
compounds was determined by the MTT quantitative colorimetric assay based on the reduction of the  
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) into purple formazan by 
mitochondrial dehydrogenases of living cells. Briefly, HepG2 and Chang cells were plated at 5 × 104 cells/ 
well in 96-well plates containing 200 μL RPMI. After an overnight incubation, cells were washed with 
fresh medium and incubated with the compounds in RPMI. After a 72 h incubation, cells were washed, and 
50 µL FBS-free medium containing 5 mg/mL MTT were added. The medium was discarded after 4 h 
incubation at 37 °C, and formazan blue formed in the cells was dissolved in DMSO. The absorbance at  
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540 nm was measured in a microplate reader (Bio-RAD, Hercules, CA, USA). The growth inhibition 
activity of compounds was defined as GI50 value, which represents the log of the molar concentration of 
the compound that inhibits 50% cell growth. 
3.3.2. Cell Cycle Analysis  
Cell cycle stage was analyzed by flow cytometry. Aliquots of 1 × 106 cells were harvested by 
centrifugation, washed with PBS and incubated in the dark in a PBS solution containing 20 μg/mL 
propidium iodide (PI) and 200 μg/mL RNase, for 30 min, at room temperature. Then samples were 
subjected to fluorescence-activated cell sorting (FACS) analysis by Epics XL™ flow cytometer  
using Expo32 software (Beckman Coulter, Fullerton, CA, USA). At least 1 × 104 cells were analyzed for 
each sample. 
3.3.3. Measurement of Phosphatidylserine Exposure  
The apoptosis-induced PS externalization to the cell surface was measured by flow cytometry by double 
staining with Annexin V-Fluorescein isothiocyanate (Annexin V-FITC)/propidium iodide (PI). Annexin V 
binding to phosphatidylserine is used to identify the earliest stage of apoptosis. PI, which does not enter 
cells with intact membranes, is used to distinguish between early apoptotic cells (annexin V-FITC positive 
and PI negative), late apoptotic cells (annexin V-FITC/PI-double positive) or necrotic cells (annexin  
V-FITC negative and PI positive). HepG2 cells were seeded in triplicate in 24-wells culture plates at a 
density of 2.0 × 105 cells/cm2. After an overnight incubation, cells were washed with fresh medium and 
incubated with the compounds in RPMI. After 24 h, cells were harvested by trypsinization and adjusted at 
2.0 × 105 cells/mL with combining buffer. One hundred μL of cell suspended solution was added to a new 
tube, and incubated with 5 µL annexin V and 10 μL of a 20 μg/mL PI solution at room temperature in the 
dark for 15 min. Then at least 1.0 × 104 cells were immediately subjected to FACS analysis using 
appropriate 2-bidimensional gating method. 
3.3.4. Acridine Orange and Ethidium Bromide Morphological Fluorescence Dye Staining 
Acridine orange (AO) stains DNA bright green, allowing visualization of the nuclear chromatin pattern 
and stains both live and dead cells. Ethidium bromide (EB) stains DNA orange but is excluded by viable 
cells. Dual staining allows separate enumeration of populations of viable non-apoptotic, viable (early) 
apoptotic, nonviable (late) apoptotic, and necrotic cells. Live cells appear uniformly green. Early apoptotic 
cells stain green and contain bright green dots in the nuclei as a consequence of chromatin condensation 
and nuclear fragmentation. Late apoptotic cells incorporate EB and therefore stain orange, but, in contrast 
to necrotic cells, the late apoptotic cells show condensed and often fragmented nuclei. Necrotic cells stain 
orange, but have a nuclear morphology resembling that of viable cells, with no condensed chromatin. 
Briefly, after HepG2 cells were treated with 3d or 3k compounds for 24 h, the medium was discarded. 
Cells were washed with saline 5 mM phosphate buffer, pH 7.4 (PBS) and then incubated with 100 μL 
PBS containing 100 μg/mL of EB plus 100 μg/mL of AO. After 20 s, EB/AO solution was discarded and 
cells immediately visualized by means of fluorescent microscope equipped with an automatic 
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photomicrograph system (Leica, Wetzlar, Germany). Multiple photos were taken at randomly selected 
areas of the well to ensure that the data obtained are representative. 
3.3.5. Measurement of Mitochondrial Transmembrane Potential 
Mitochondrial transmembrane potential was assayed by flow cytofluorometry, using the cationic 
lipophilic dye 3,30-dihexyloxacarbocyanine iodide (Molecular Probes, Inc., Eugene, OR, USA), which 
accumulates in the mitochondrial matrix. Changes in mitochondrial membrane potential are indicated by a 
reduction in the 3,30-dihexyloxacarbocyanine iodide-induced fluorescence intensity. Cells were incubated 
with 3,30-dihexyloxacarbocyanine iodide at a 40 nmol/L final concentration, for 15 min at 37 °C. After 
centrifugation, cells were washed with PBS and suspended in 500 µL PBS. Fluorescent intensities were 
analyzed in at least 1 × 104 cells for each sample. 
3.3.6. Measurement of Intracellular Reactive Oxygen Species 
ROS level was monitored by measuring fluorescence changes that resulted from intracellular oxidation 
of 2′,7′-dichlorofluorescin diacetate (DCFH). DCFH, at 10 mM final concentration, was added to the cell 
medium 30 min before the end of the treatment. The cells were collected by centrifugation for 5 min at 
2000 rpm at 4 °C, washed, suspended in PBS and immediately subjected to fluorescence-activated cell 
sorting analysis. At least 1 × 104 cells were analyzed for each sample. 
4. Conclusions 
A new series of nortopsentin analogues in which the imidazole ring of the natural product was replaced 
by thiazole and the indole unit bound to the position 2 of thiazole was substituted by a 7-azaindole moiety 
was efficiently synthesized. Two of the new nortopsentin derivatives, 3d and 3k, showed good 
antiproliferative activity against the totality of the about 60 human tumor cell lines of NCI full panel with 
GI50 values ranging from low micromolar to nanomolar level (13.0–0.03 and 14.2–0.04 μM, respectively. 
Moreover, they have shown potent cytotoxic activity on HepG2 hepatocarcinoma cells, while under 
identical conditions, they did not affect normal immortalized human liver cells (Chang). Both the 
compounds induced a concentration-dependent accumulation of cells in the subG0/G1phase while confined 
viable cells in G2/M phase. The mechanism of the anti-proliferative effect of the nortopsentin derivatives 
was pro-apoptotic, being associated with externalization of plasma membrane phosphatidylserine and 
mitochondrial dysfunction. 
Acknowledgments 
This work was financially supported by Ministero dell’Istruzione dell’Università e della  
Ricerca (MIUR). 
Author Contributions 
Anna Carbone, Barbara Parrino, Gloria Di Vita Virginia Spanò, Alessandra Montalbano performed 
chemical research and analyzed the data. Alessandro Attanzio, Luisa Tesoriere, and Maria Antonia Livrea, 
performed biological research and analysed the data. Girolamo Cirrincione, Patrizia Diana, Paola Barraja, 
Mar. Drugs 2015, 13 1920 
 
 
Luisa Tesoriere, Maria Antonia Livrea, participated in the design of the research and the writing of the 
manuscript. All authors read and approved the final manuscript. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References and Notes 
1. Barraja, P.; Spanò, V.; Diana, P.; Carbone, A.; Cirrincione, G.; Vedaldi, D.; Salvador, A.; Viola, G.; 
Dall’Acqua, F. Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogue. Bioorg. Med. Chem. 
Lett. 2009, 19, 1711−1714. 
2. Montalbano, A.; Parrino, B.; Diana, P.; Barraja, P.; Carbone, A.; Spanò, V.; Cirrincione, G. 
Synthesis of the new oligopeptide pyrrole derivative isonetropsin and its one pyrrole unit 
analogue. Tetrahedron 2013, 69, 2550−2554. 
3. Barraja, P.; Spanò, V.; Diana, P.; Carbone, A.; Cirrincione, G. Synthesis of the new ring system 
6,8-dihydro-5H-pyrrolo[3,4-h]-quinazoline. Tetrahedron Lett. 2009, 50, 5389−5391. 
4. Barraja, P.; Caracausi, L.; Diana, P.; Carbone, A.; Montalbano, A.; Cirrincione, G.; Brun, P.;  
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